PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), …

CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the U.S. Food and Drug Administration (FDA) approval of ZEVASKYN™ (prademagene zamikeracel) on April 28, 2025.

GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2025. “We made significant progress in the first quarter of 2025, advancing our …

PLANTATION, Fla.--(BUSINESS WIRE)--Chewy, Inc. (NYSE: CHWY), a trusted destination for pet parents and partners everywhere, announced today that the Company's Chief Financial Officer, David Reeder, will be departing in several months to return to the semiconductor industry as a Chief Executive Officer. “We appreciate David's contributions during his time at Chewy and thank him for his leadership as we advanced our strategic, long-term growth initiatives,” said Sumit Singh, Chief Executive Offic.

Twelfth annual report reinforces commitments and demonstrates ongoing progress toward sustainability strategy and related priorities Twelfth annual report reinforces commitments and demonstrates ongoing progress toward sustainability strategy and related priorities

OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million compared to consolidated revenue for the third quarter of fiscal year 2024 of $376.4 million. Consolidated net income for the third quarter of fiscal year 2025 was $26.0 million compared to consolidated net income for the third quarter of fiscal year 2024 of $8.6 million. Finally, consolidated Adjusted EBITDA* for the third quarter of fis.

ENB Q1 earnings and revenues beat estimates, driven by higher Adjusted EBITDA contributions across its key business segments. Revenues also increase from the prior-year level.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148006&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Avis Budget Group, Inc. (NASDAQ:CAR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/avis-budget-lawsuit-submission-form?prid=148007&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148008&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Open Lending Corporation (NASDAQ:LPRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/open-lending-corporation-lawsuit-submission-form?prid=148005&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=148009&wire=1 or contact Joseph E. Levi, Esq.

HOUSTON--(BUSINESS WIRE)--NRG Energy, Inc. (NYSE: NRG) today reports GAAP Net Income of $750 million for the three months ended March 31, 2025. GAAP EPS — basic is $3.70, Cash Provided by Operating Activities is $855 million, Adjusted Net Income is $531 million, Adjusted EPS is $2.68, Adjusted EBITDA is $1,126 million, and Free Cash Flow before Growth Investments (FCFbG) is $293 million for the first quarter of 2025. “NRG achieved exceptional financial and operational performance in the first q.

Designed to provide broad exposure to the Energy - Broad segment of the equity market, the Strive U.S. Energy ETF (DRLL) is a passively managed exchange traded fund launched on 08/09/2022.

Launched on 05/08/2007, the First Trust Natural Gas ETF (FCG) is a smart beta exchange traded fund offering broad exposure to the Energy ETFs category of the market.

Launched on 02/23/2007, the WisdomTree U.S. LargeCap ETF (EPS) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.

Designed to provide broad exposure to the Financials - Brokers/ Capital markets segment of the equity market, the SPDR S&P Capital Markets ETF (KCE) is a passively managed exchange traded fund launched on 11/08/2005.

A smart beta exchange traded fund, the First Trust Consumer Discretionary AlphaDEX ETF (FXD) debuted on 05/08/2007, and offers broad exposure to the Consumer Discretionary ETFs category of the market.

Launched on 05/01/2006, the iShares U.S. Insurance ETF (IAK) is a passively managed exchange traded fund designed to provide a broad exposure to the Financials - Insurance segment of the equity market.